Prestige Consumer Healthcare (NYSE:PBH) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBHFree Report) from a hold rating to a buy rating in a research note released on Saturday.

Other equities research analysts also recently issued research reports about the company. BMO Capital Markets lowered their price target on Prestige Consumer Healthcare from $124.00 to $117.00 and set an outperform rating for the company in a report on Wednesday, November 15th. Royal Bank of Canada reduced their target price on Prestige Consumer Healthcare from $110.00 to $103.00 and set a sector perform rating for the company in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of Moderate Buy and an average price target of $97.00.

Check Out Our Latest Stock Analysis on Prestige Consumer Healthcare

Prestige Consumer Healthcare Trading Down 0.9 %

Shares of PBH opened at $68.02 on Friday. The company’s fifty day simple moving average is $61.14 and its 200-day simple moving average is $60.22. The company has a market cap of $3.38 billion, a P/E ratio of -41.48, a P/E/G ratio of 1.98 and a beta of 0.50. The company has a current ratio of 3.09, a quick ratio of 1.92 and a debt-to-equity ratio of 0.75. Prestige Consumer Healthcare has a twelve month low of $55.96 and a twelve month high of $69.29.

Prestige Consumer Healthcare (NYSE:PBHGet Free Report) last announced its quarterly earnings data on Thursday, February 8th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.04 by $0.02. The company had revenue of $282.74 million during the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $1.04 EPS. As a group, analysts expect that Prestige Consumer Healthcare will post 4.33 EPS for the current year.

Insider Buying and Selling

In other news, SVP Mary Beth Fritz sold 5,336 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $69.00, for a total value of $368,184.00. Following the transaction, the senior vice president now directly owns 15,934 shares of the company’s stock, valued at $1,099,446. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBH. SG Americas Securities LLC purchased a new stake in shares of Prestige Consumer Healthcare during the third quarter worth approximately $1,632,000. TD Asset Management Inc increased its holdings in Prestige Consumer Healthcare by 11.1% in the third quarter. TD Asset Management Inc now owns 46,100 shares of the company’s stock valued at $2,636,000 after buying an additional 4,600 shares during the last quarter. Jennison Associates LLC raised its stake in Prestige Consumer Healthcare by 3.0% in the third quarter. Jennison Associates LLC now owns 477,821 shares of the company’s stock valued at $27,327,000 after buying an additional 13,871 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Prestige Consumer Healthcare during the 3rd quarter worth about $877,000. Finally, Pinnacle Associates Ltd. purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $1,454,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Featured Articles

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.